| Bioactivity | LM2I is a derivative of Spinosyn A (SPA). LM2I is argininosuccinate synthase (ASS1) enzyme activator, and tumor inhibitor that directly interact with ASS1. LM2I has significant antiproliferative activity in seven colorectal cancer cell-lines and xenograft tumors of colorectal cancer. LM2I inhibits colorectal cancer cell growth via the EGFR pathway[1]. |
| Target | Argininosuccinate synthetase (ASS1) |
| Invitro | LM2I (0µM~10µM, 48h)结直肠癌细胞系有较强的抑制作用[1]。LM2I(2µM, 15d)在结直肠癌细胞中抑制EGFR通路[1]。LM2I通过EGFR抑制结直肠癌癌症细胞[1]。 0 --> LM2I 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | LM2I (2.5 mg/kg， 腹腔注射, 每隔一天共28天) 抑制了裸鼠异种移植瘤模型肿瘤的生长[1]。 Animal Model: |
| Name | LM2I |
| Formula | C47H77N3O11 |
| Molar Mass | 860.13 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Peng K, et al. Spinosyn A and Its Derivative Inhibit Colorectal Cancer Cell Growth via the EGFR Pathway. J Nat Prod. 2023 Sep 8. |